The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action

Resveratrol Improves Mitochondrial Function and Protects against Metabolic Disease by Activating SIRT1 and PGC-1α

Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.013 · Cited by 4,057 · see citing works

Biology of Incretins: GLP-1 and GIP

Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · see citing works

A central role for JNK in obesity and insulin resistance

Hirosumi, J., Tuncman, G., Chang, L., Görgün, C. Z., Uysal, K. T., Maeda, K., Karin, M., & Hotamisligil, G. S. (2002) · Nature · doi:10.1038/nature01137 · Cited by 3,359 · see citing works

The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years

Hely, M. A., Reid, W. G. J., ADENA, M. A., Halliday, G. M., & Morris, J. G. (2008) · Movement Disorders · doi:10.1002/mds.21956 · Cited by 2,245 · see citing works

Crosstalk in NF-κB Signaling Pathways

Oeckinghaus, A., Hayden, M. S., & Ghosh, S. (2011) · Nature Immunology · doi:10.1038/ni.2065 · Cited by 1,942 · see citing works

PGC-1α, SIRT1 and AMPK, an energy sensing network that controls energy expenditure

Cantó, C., & Auwerx, J. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328328d0a4 · Cited by 1,624 · see citing works

Distinct morphological stages of dentate granule neuron maturation in the adult mouse hippocampus

Zhao, C., Teng, E. M., Summers, R. G., Ming, G.-L., & Gage, F. H. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3648-05.2006 · Cited by 1,257 · see citing works

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.

Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124 · see citing works

Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease

Nagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E., Shaked, G. M., Wang, L., Blesch, A., Kim, A., Conner, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1912 · Cited by 1,034 · see citing works

Cognitive profile of patients with newly diagnosed Parkinson disease

Muslimović, D., Post, B., Speelman, J. D., & Schmand, B. (2005) · Neurology · doi:10.1212/01.wnl.0000180516.69442.95 · Cited by 1,007 · see citing works

The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort

Williams‐Gray, C. H., Evans, J., Goris, A., Foltynie, T., Ban, M., Robbins, T. W., Brayne, C., Kolachana, B. S., Weinberger, D. R., Sawcer, S. J., et al. (2009) · Brain · doi:10.1093/brain/awp245 · Cited by 970 · see citing works

Dopamine depletion impairs precursor cell proliferation in Parkinson disease

Höglinger, G. U., Rizk, P., Mp, M., Duyckaerts, C. J., Oertel, W. H., Caillé, I., & Hirsch, É. C. (2004) · Nature Neuroscience · doi:10.1038/nn1265 · Cited by 946 · see citing works

Mitochondria in the aetiology and pathogenesis of Parkinson's disease

Schapira, A. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70327-7 · Cited by 883 · see citing works

Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies

Irwin, D. J., Lee, V. M. ‐., & Trojanowski, J. Q. (2013) · Nature reviews. Neuroscience · doi:10.1038/nrn3549 · Cited by 875 · see citing works

PGC-1 α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease

Zheng, B., Liao, Z., Locascio, J. J., Lesniak, K. A., Roderick, S. S., Watt, M. L., Eklund, A. C., Zhang‐James, Y., Kim, P. D., Hauser, M. A., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001059 · Cited by 854 · see citing works

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851 · see citing works

Microglial activation and dopamine terminal loss in early Parkinson's disease

Ouchi, Y., Yoshikawa, E., Sekine, Y., Futatsubashi, M., Kanno, T., Ogusu, T., & Torizuka, T. (2005) · Annals of Neurology · doi:10.1002/ana.20338 · Cited by 846 · see citing works

Hypothalamic programming of systemic ageing involving IKK-β, NF-κB and GnRH

Zhang, G., Li, J., Purkayastha, S., Tang, Y., Zhang, H., Yin, Y., Li, B., Liu, G., & Cai, D. (2013) · Nature · doi:10.1038/nature12143 · Cited by 834 · cited 1× · see citing works

An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease–associated Aβ oligomers

Bomfim, T. R., Forny‐Germano, L., Sathler, L. B., Brito‐Moreira, J., Houzel, J., Decker, H., Silverman, M. A., Kazi, H., Melo, H. M., McClean, P. L., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci57256 · Cited by 830 · see citing works

Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson's disease

Petzinger, G. M., Fisher, B. E., McEwen, S., Beeler, J. A., Walsh, J. P., & Jakowec, M. W. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70123-6 · Cited by 798 · see citing works

Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains

Imamura, K., Hishikawa, N., Sawada, M., Nagatsu, T., Yoshida, M., & Hashizume, Y. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0766-2 · Cited by 791 · see citing works

The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease

McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698 · see citing works

Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans

Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696 · see citing works

The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort

Williams‐Gray, C. H., Mason, S., Evans, J., Foltynie, T., Brayne, C., Robbins, T. W., & Barker, R. A. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-305277 · Cited by 683 · see citing works

Nuclear translocation of NF-κB is increased in dopaminergic neurons of patients with Parkinson disease

Hunot, S., Brugg, B., Ricard, D., Michel, P. P., Muriel, M., Ruberg, M., Faucheux, B. A., Agid, Y., & Hirsch, É. C. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7531 · Cited by 678 · see citing works

Incretin-based therapies for type 2 diabetes mellitus

Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 645 · see citing works

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents

Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645 · see citing works

Mash1regulates neurogenesis in the ventral telencephalon

Casarosa, S., Schuurmans, C. J., & Guillemot, F. (1999) · Development · doi:10.1242/dev.126.3.525 · Cited by 639 · see citing works

β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease

Masliah, E., Rockenstein, E., Veinbergs, I., Sagara, Y., Mallory, M., Hashimoto, M., & Mucke, L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211412398 · Cited by 607 · see citing works

GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK

Beiroa, D., Imbernon, M., Gallego, R., Senra, A., Herranz, D., Villarroya, F., Serrano, M., Fernø, J., Salvador, J., Escalada, J., et al. (2014) · Diabetes · doi:10.2337/db14-0302 · Cited by 602 · see citing works

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism

Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589 · see citing works

Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?

Compta, Y., Parkkinen, L., O’Sullivan, S. S., Vandrovcová, J., Holton, J. L., Collins, C., Lashley, T., Kallis, C., Williams, D. R., de Silva, R., et al. (2011) · Brain · doi:10.1093/brain/awr031 · Cited by 585 · see citing works

Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease.

Perry, E. K., Curtis, M., Dick, D. J., Candy, J., Atack, J. R., Bloxham, C. A., Blessed, G., FAIRBAIRN, A. F., Tomlinson, B. E., & Perry, R. H. (1985) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.48.5.413 · Cited by 572 · see citing works

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): A randomised, open-label study

Buse, J. B., Nauck, M., Forst, T., Sheu, W. H.-H., Shenouda, S. K., Heilmann, C. R., Hoogwerf, B. J., Gao, A., Boardman, M. K., Fineman, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61267-7 · Cited by 565 · see citing works

Cortical Cholinergic Function Is More Severely Affected in Parkinsonian Dementia Than in Alzheimer Disease

Bohnen, N. I., Kaufer, D., Ivanco, L. S., Lopresti, B. J., Koeppe, R. A., Davis, J. G., Mathis, C. A., Moore, R. Y., & DeKosky, S. T. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1745 · Cited by 551 · see citing works

Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4

Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548 · see citing works

Insulin, insulin-degrading enzyme and amyloid-β peptide in Alzheimer's disease: review and hypothesis

Qiu, W. Q., & Folstein, M. F. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.01.004 · Cited by 538 · see citing works

Exenatide and the treatment of patients with Parkinson's disease

Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529 · see citing works

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

Hunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504 · see citing works

Neurons Regulate Extracellular Levels of Amyloid β-Protein via Proteolysis by Insulin-Degrading Enzyme

Vekrellis, K., Ye, Z., Qiu, W. Q., Walsh, D. M., Hartley, D. M., Chesneau, V., Rosner, M. R., & Selkoe, D. J. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-05-01657.2000 · Cited by 495 · see citing works

SIRT1 in Neurodevelopment and Brain Senescence

Herskovits, A. Z., & Guarente, L. (2014) · Neuron · doi:10.1016/j.neuron.2014.01.028 · Cited by 493 · see citing works

α-Synuclein Is Localized to Mitochondria-Associated ER Membranes

Guardia-Laguarta, C., Area-Gómez, E., Rüb, C., Liu, Y.-H., Magrané, J., Becker, D., Voos, W., Schon, E., & Przedborski, S. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.2507-13.2014 · Cited by 489 · see citing works

Insulin resistance in brain alters dopamine turnover and causes behavioral disorders

Kleinridders, A., Cai, W., Cappellucci, L., Ghazarian, A., Collins, W. R., Vienberg, S. G., Pothos, E. N., & Kahn, C. R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500877112 · Cited by 486 · see citing works

Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain

Cork, S. C., Richards, J. E., Holt, M. K., Gribble, F. M., Reimann, F., & Trapp, S. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.07.008 · Cited by 478 · see citing works

Pathological changes in the nucleus of meynert in Alzheimer's and Parkinson's diseases

Candy, J., Perry, R. H., Perry, E. K., Irving, D., Blessed, G., FAIRBAIRN, A. F., & Tomlinson, B. E. (1983) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(83)90045-x · Cited by 463 · see citing works

Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer’s disease pathology

Griffin, R. J., Moloney, A., Kelliher, M., Johnston, J. A., Ravid, R., Dockery, P., O'Connor, R., & O'Neill, C. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02949.x · Cited by 459 · see citing works

Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease

Ghosh, A., Roy, A., Liu, X., Kordower, J. H., Mufson, E. J., Hartley, D. M., Ghosh, S., Mosley, R. L., Gendelman, H. E., & Pahan, K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704908104 · Cited by 438 · see citing works

SIRT1 and SIRT2: emerging targets in neurodegeneration

Dönmez, G., & Outeiro, T. F. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302451 · Cited by 414 · see citing works

Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes

Kodera, R., Shikata, K., Kataoka, H. U., Takatsuka, T., Miyamoto, S., Sasaki, M., Kajitani, N., Nishishita, S., Sarai, K., Hirota, D., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-2028-x · Cited by 394 · see citing works

Dementia in Parkinson disease

Hilker, R., Thomas, A. V., Klein, J. C., Weisenbach, S., Kalbe, E., Burghaus, L., Jacobs, A. H., Herholz, K., & Wd, H. (2005) · Neurology · doi:10.1212/01.wnl.0000191154.78131.f6 · Cited by 383 · see citing works

Protection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4

Perry, T., Haughey, N. J., Mattson, M. P., Egan, J. M., & Greig, N. H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.037481 · Cited by 380 · see citing works

Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia

Bohnen, N. I., Kaufer, D. I., Hendrickson, R., Ivanco, L. S., Lopresti, B. J., Constantine, G. M., Mathis, C. A., Davis, J. G., Moore, R. Y., & DeKosky, S. T. (2006) · Journal of Neurology · doi:10.1007/s00415-005-0971-0 · Cited by 364 · see citing works

Entry of exendin-4 into brain is rapid but may be limited at high doses

Kastin, A., & Akerstrom, V. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802206 · Cited by 362 · see citing works

Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease

Ferreira, S. T., Clarke, J. R., Bomfim, T. R., & Felice, F. G. D. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.12.010 · Cited by 354 · see citing works

Glucagon‐like peptide‐1 decreases endogenous amyloid‐β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron

Perry, T., Lahiri, D. K., Sambamurti, K., Chen, D., Mattson, M. P., Egan, J. M., & Greig, N. H. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10611 · Cited by 347 · see citing works

Peptide hormone exendin‐4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease

Bertilsson, G., Patrone, C., Zachrisson, O., Andersson, A., Dannaeus, K., Heidrich, J., Kortesmaa, J., Mercer, A., Nielsen, E., Rönnholm, H., et al. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21483 · Cited by 345 · see citing works

How does brain insulin resistance develop in Alzheimer's disease?

De Felice, F. G., Lourenco, M. V., & Ferreira, S. T. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.004 · Cited by 337 · see citing works

Pathogenesis of Parkinson's disease

Hirsch, E. C., Jenner, P., & Przedborski, S. (2013) · Movement Disorders · doi:10.1002/mds.25032 · Cited by 336 · see citing works

Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?

Tayebi, N. (2003) · Molecular Genetics and Metabolism · doi:10.1016/s1096-7192(03)00071-4 · Cited by 327 · see citing works

Insulin in Central Nervous System: More than Just a Peripheral Hormone

Duarte, A. I., Moreira, P. I., & Oliveira, C. R. (2012) · Journal of Aging Research · doi:10.1155/2012/384017 · Cited by 324 · see citing works

Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes

Lee, Y.-S., Park, M.-S., Choung, J.-S., Kim, S.-S., Oh, H.-H., Choi, C.-S., Ha, S.-Y., Kang, Y., Kim, Y., & Jun, H.-S. (2012) · Diabetologia · doi:10.1007/s00125-012-2592-3 · Cited by 319 · see citing works

GLP-1 Receptor Stimulation Reduces Amyloid-β Peptide Accumulation and Cytotoxicity in Cellular and Animal Models of Alzheimer's Disease

Li, Y., Duffy, K. B., Ottinger, M. A., Ray, B., Bailey, J. A., Holloway, H. W., Tweedie, D., Perry, T., Mattson, M. P., Kapogiannis, D., et al. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1314 · Cited by 319 · see citing works

Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits

Drucker, D. J., Sherman, S. I., Gorelick, F. S., Bergenstal, R. M., Sherwin, R. S., & Buse, J. B. (2010) · Diabetes Care · doi:10.2337/dc09-1499 · Cited by 316 · see citing works

The expression of GLP‐1 receptor mRNA and protein allows the effect of GLP‐1 on glucose metabolism in the human hypothalamus and brainstem

Álvarez, E., Martínez, M. D., Roncero, I., Chowen, J. A., Cuartero, B. G., Gispert, J. D., Sanz, C., Vázquez, P., Maldonado, A., Cáceres, J. D., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02914.x · Cited by 307 · see citing works

A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells.

Perry, T., Lahiri, D., Chen, D., Zhou, J., Shaw, K., Egan, J., & Greig, N. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.958 · Cited by 306 · see citing works

Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease

Avilés-Olmos, I., Dickson, J. C., Kefalopoulou, Z. M., Djamshidian, A., Kahan, J., Ell, P. J., Whitton, P. S., Wyse, R. K. H., Isaacs, T., Lees, A. J., et al. (2014) · Journal of Parkinson s Disease · doi:10.3233/jpd-140364 · Cited by 300 · see citing works

PI3-kinase/Akt/mTOR signaling: Impaired on/off switches in aging, cognitive decline and Alzheimer's disease

Neill, C. O. (2013) · Experimental Gerontology · doi:10.1016/j.exger.2013.02.025 · Cited by 292 · see citing works

Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease

Harkavyi, A., Abuirmeileh, A. N., Lever, R., Kingsbury, A. E., Biggs, C. S., & Whitton, P. S. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-19 · Cited by 290 · see citing works

Synaptic Dysfunction in Parkinson’s Disease

Picconi, B., Piccoli, G., & Calabresi, P. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-3-7091-0932-8_24 · Cited by 290 · see citing works

Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease

Jellinger, K. A., Seppi, K., Wenning, G. K., & Poewe, W. H. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200027 · Cited by 287 · see citing works

Effects of proinflammatory cytokines on the growth, fate, and motility of multipotential neural precursor cells

Ben‐Hur, T., Menachem-Zidon, O. B., Furer, V. L., Einstein, O., Mizrachi‐Kol, R., & Grigoriadis, N. (2003) · Molecular and Cellular Neuroscience · doi:10.1016/s1044-7431(03)00218-5 · Cited by 283 · see citing works

Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease

Abbas, T. F., Faivre, É., & Hölscher, C. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.06.035 · Cited by 282 · see citing works

Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease

Golpich, M., Amini, E., Hemmati, F., Ibrahim, N. M., Rahmani, B., Mohamed, Z., Raymond, A. A., Dargahi, L., Ghasemi, R., & Ahmadiani, A. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.03.010 · Cited by 276 · see citing works

α‐Synuclein contributes to GSK‐3β‐catalyzed Tau phosphorylation in Parkinson's disease models

Duka, T., Duka, V., Joyce, J. N., & Sidhu, A. (2009) · The FASEB Journal · doi:10.1096/fj.08-120410 · Cited by 276 · see citing works

Neuroprotective and neurotrophic actions of glucagon‐like peptide‐1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders

Salcedo, I., Tweedie, D., Li, Y., & Greig, N. H. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01971.x · Cited by 263 · see citing works

Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease

Kim, S., Moon, M., & Park, S. (2009) · Journal of Endocrinology · doi:10.1677/joe-09-0132 · Cited by 263 · see citing works

Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease

Liu, W., Jalewa, J., Sharma, M., Li, G., Li, L., & Hölscher, C. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.06.054 · Cited by 246 · see citing works

Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes

Drucker, D. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.1.87 · Cited by 237 · see citing works

Intracellular Signals Mediating the Food Intake-Suppressive Effects of Hindbrain Glucagon-like Peptide-1 Receptor Activation

Hayes, M. R., Leichner, T. M., Zhao, S., Lee, G., Chowansky, A., Zimmer, D. J., Jonghe, B. C. D., Kanoski, S. E., Grill, H. J., & Bence, K. K. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.02.001 · Cited by 234 · see citing works

Plasma Ceramide and Glucosylceramide Metabolism Is Altered in Sporadic Parkinson's Disease and Associated with Cognitive Impairment: A Pilot Study

Mielke, M. M., Maetzler, W., Haughey, N. J., Bandaru, V. V. R., Savica, R., Deuschle, C., Gasser, T., Hauser, A., Gräber‐Sultan, S., Schleicher, E. D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073094 · Cited by 232 · see citing works

RTP801 Is Induced in Parkinson's Disease and Mediates Neuron Death by Inhibiting Akt Phosphorylation/Activation

Malagelada, C., Jin, Z. H., & Greene, L. A. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3928-08.2008 · Cited by 228 · see citing works

Shared dysregulated pathways lead to Parkinson's disease and diabetes

Santiago, J. A., & Potashkin, J. A. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.01.002 · Cited by 226 · see citing works

Allosteric Ligands of the Glucagon-Like Peptide 1 Receptor (GLP-1R) Differentially Modulate Endogenous and Exogenous Peptide Responses in a Pathway-Selective Manner: Implications for Drug Screening

Koole, C., Wootten, D. L., Simms, J., Valant, C., Sridhar, R., Woodman, O. L., Miller, L. J., Summers, R. J., Christopoulos, A., & Sexton, P. M. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.065664 · Cited by 225 · see citing works

Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE ‐ NF κB and Nrf2‐antioxidant signaling pathways

Abdelsalam, R. M., & Safar, M. M. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13087 · Cited by 222 · see citing works

In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease

Iannaccone, S., Cerami, C., Alessio, M., Garibotto, V., Panzacchi, A., Olivieri, S., Gelsomino, G., Moresco, R. M., & Perani, D. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.07.002 · Cited by 221 · see citing works

Influence of microglial activation on neuronal function in Alzheimer's and Parkinson's disease dementia

Fan, Z., Aman, Y., Ahmed, I., Chetelat, G., Landeau, B., Ray Chaudhuri, K., Brooks, D. J., & Edison, P. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.016 · Cited by 212 · see citing works

New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson's disease

Calabresi, P., Castrioto, A., Filippo, M. D., & Picconi, B. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70118-2 · Cited by 211 · see citing works

Novel GLP‐1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain

Hamilton, A., Patterson, S., Porter, D., Gault, V. A., & Holscher, C. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22565 · Cited by 210 · see citing works

Involvement of Akt in neurite outgrowth

Read, D. E., & Gorman, A. M. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0057-8 · Cited by 210 · see citing works

Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF

O’Keeffe, G. C., Tyers, P., Aarsland, D., Dalley, J. W., Barker, R. A., & Caldwell, M. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803955106 · Cited by 207 · see citing works

Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells

Wang, Q., Li, L., Xu, E., Wong, V. S. C., Rhodes, C. J., & Brubaker, P. L. (2004) · Diabetologia · doi:10.1007/s00125-004-1327-5 · Cited by 206 · see citing works

Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes

Drucker, D. J. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/eoid.12.1.87.21250 · Cited by 204 · see citing works

Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Provides Neuroprotection in Mice Transient Focal Cerebral Ischemia

Teramoto, S., Miyamoto, N., Yatomi, K., Tanaka, Y., Oishi, H., Arai, H., Hattori, N., & Urabe, T. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.51 · Cited by 201 · see citing works

M1 and M2 immune activation in Parkinson’s Disease: Foe and ally?

Moehle, M. S., & West, A. B. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.11.018 · Cited by 198 · see citing works

Pathologic Accumulation of α-Synuclein and Aβ in Parkinson Disease Patients With Dementia

Kotzbauer, P. T., Cairns, N. J., Campbell, M. C., Willis, A. W., Racette, B. A., Tabbal, S. D., & Perlmutter, J. S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1608 · Cited by 197 · see citing works

Expression and Distribution of Glucagon-Like Peptide-1 Receptor mRNA, Protein and Binding in the Male Nonhuman Primate (Macaca mulatta) Brain

Heppner, K. M., Kirigiti, M. A., Secher, A., Paulsen, S. J., Buckingham, R., Pyke, C., Knudsen, L. B., Vrang, N., & Grove, K. L. (2014) · Endocrinology · doi:10.1210/en.2014-1675 · Cited by 195 · see citing works

Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease

McClean, P. L., Gault, V. A., Harriott, P., & Hölscher, C. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.12.023 · Cited by 193 · see citing works

Akt signal transduction dysfunction in Parkinson's disease

Timmons, S., Coakley, M. F., Moloney, A. M., & Neill, C. O. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.09.055 · Cited by 192 · see citing works

The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer’s Disease

Hansen, H. H., Fabricius, K., Barkholt, P., Niehoff, M. L., Morley, J. E., Jelsing, J., Pyke, C., Knudsen, L. B., Farr, S. A., & Vrang, N. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-143090 · Cited by 189 · see citing works

Saxagliptin: A dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease

Kosaraju, J., Gali, C. C., Khatwal, R. B., Dubala, A., Chinni, S., Holsinger, R. M. D., Madhunapantula, S. V., Nataraj, S. K. M., & Basavan, D. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.008 · Cited by 189 · see citing works

[11C]-PK11195 PET: Quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease?

Bartels, A. L., Willemsen, A. T. M., Doorduin, J., de Vries, E. F. J., Dierckx, R. A., & Leenders, K. L. (2009) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2009.05.005 · Cited by 181 · see citing works

Microglial Activation and Antioxidant Responses Induced by the Parkinson’s Disease Protein α-Synuclein

Béraud, D., Hathaway, H. A., Trecki, J., Chasovskikh, S., Johnson, D. A., Johnson, J. A., Federoff, H. J., Shimoji, M., Mhyre, T. R., & Maguire‐Zeiss, K. A. (2012) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-012-9401-0 · Cited by 175 · see citing works

Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson’s Disease?

Leal, M. C., Casabona, J. C., Puntel, M., & Pitossi, F. J. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00053 · Cited by 175 · see citing works

Activation of AMPK and inactivation of Akt result in suppression of mTOR-mediated S6K1 and 4E-BP1 pathways leading to neuronal cell death in in vitro models of Parkinson's disease

Xu, Y., Liu, C., Chen, S., Ye, Y., Guo, M., Ren, Q., Liu, L., Zhang, H., Xu, C., Zhou, Q., et al. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.04.009 · Cited by 171 · see citing works

Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms

Kumar, P., Padi, S. S., Naidu, P. S., & Kumar, A. (2006) · Behavioural Pharmacology · doi:10.1097/00008877-200609000-00014 · Cited by 167 · see citing works

Neural and Immune Mechanisms in the Pathogenesis of Parkinson’s Disease

Blandini, F. (2013) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-013-9435-y · Cited by 164 · see citing works

Neurodegeneration in an animal model of Parkinson’s disease is exacerbated by a high-fat diet

Morris, J. K., Bomhoff, G. L., Stanford, J. A., & Geiger, P. C. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00449.2010 · Cited by 163 · see citing works

Platelet-Derived Growth Factor (PDGF-BB) and Brain-Derived Neurotrophic Factor (BDNF) induce striatal neurogenesis in adult rats with 6-hydroxydopamine lesions

Mohapel, P., Frielingsdorf, H., Häggblad, J., Zachrisson, O., & Brundin, P. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2004.11.056 · Cited by 161 · see citing works

Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice

Gengler, S., McClean, P. L., McCurtin, R. E., Gault, V. A., & Hölscher, C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.02.014 · Cited by 160 · see citing works

The extra‐pancreatic effects of <scp>GLP‐1</scp> receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems

Seufert, J., & Gallwitz, B. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12251 · Cited by 156 · see citing works

The Diabetes Drug Liraglutide Ameliorates Aberrant Insulin Receptor Localisation and Signalling in Parallel with Decreasing Both Amyloid-β Plaque and Glial Pathology in a Mouse Model of Alzheimer’s Disease

Long-Smith, C. M., Manning, S., McClean, P. L., Coakley, M. F., O’Halloran, D., Hölscher, C., & O’Neill, C. (2012) · NeuroMolecular Medicine · doi:10.1007/s12017-012-8199-5 · Cited by 156 · see citing works

GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid

Gault, V. A., & Hölscher, C. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.03.025 · Cited by 155 · see citing works

Neurotrophic factor therapy for Parkinson’s disease

Rangasamy, S. B., Soderstrom, K. E., Bakay, R. A. E., & Kordower, J. H. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)84013-0 · Cited by 155 · see citing works

Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson's disease

Abbott, S. K., Li, H., Muñoz, S. S., Knoch, B., Batterham, M. J., Murphy, K. E., Halliday, G. M., & Garner, B. (2013) · Movement Disorders · doi:10.1002/mds.25729 · Cited by 154 · see citing works

Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer’s prone mice

D’Amico, M., Filippo, C. D., Marfella, R., Abbatecola, A. M., Ferraraccio, F., Rossi, F., & Paolisso, G. (2009) · Experimental Gerontology · doi:10.1016/j.exger.2009.12.004 · Cited by 154 · see citing works

Neuroprotective properties of GLP-1: theoretical and practical applications

Holst, J. J., Burcelin, R., & Nathanson, E. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.549466 · Cited by 152 · see citing works

The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test

Isacson, R., Nielsen, E. I., Dannaeus, K., Bertilsson, G., Patrone, C., Zachrisson, O., & Wikström, L. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.10.008 · Cited by 150 · see citing works

Insulin resistance impairs nigrostriatal dopamine function

Morris, J. K., Bomhoff, G. L., Gorres, B. K., Davis, V. A., Kim, J., Lee, P., Brooks, W. M., Gerhardt, G. A., Geiger, P. C., & Stanford, J. A. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.06.005 · Cited by 150 · see citing works

Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson’s disease

Costa, C., Sgobio, C., Siliquini, S., Tozzi, A., Tantucci, M., Ghiglieri, V., Filippo, M. D., Pendolino, V., de Iure, A., Marti, M., et al. (2012) · Brain · doi:10.1093/brain/aws101 · Cited by 150 · see citing works

Regulation of Adipocyte Formation by GLP-1/GLP-1R Signaling

Challa, T. D., Beaton, N., Arnold, M., Rudofsky, G., Langhans, W., & Wolfrum, C. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.310342 · Cited by 149 · see citing works

Hepatic Ceramide May Mediate Brain Insulin Resistance and Neurodegeneration in Type 2 Diabetes and Non-alcoholic Steatohepatitis

Lyn‐Cook, L. E., Lawton, M., Tong, M., Silbermann, E., Longato, L., Jiao, P., Mark, P., Wands, J. R., Xu, H., & de la Monte, S. M. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0984 · Cited by 149 · see citing works

Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary‐induced obesity and insulin resistance

Porter, D. W., Kerr, B. D., Flatt, P. R., Hölscher, C., & Gault, V. A. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01259.x · Cited by 148 · see citing works

Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease

Kosaraju, J., Murthy, V., Khatwal, R. B., Dubala, A., Chinni, S., Nataraj, S. K. M., & Basavan, D. (2013) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12148 · Cited by 146 · see citing works

Age and dementia-associated atrophy predominates in the hippocampal head and amygdala in Parkinson's disease

Bouchard, T. P., Malykhin, N. V., Martin, W. R. W., Hanstock, C. C., Emery, D. J., Fisher, N., & Camicioli, R. M. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.002 · Cited by 146 · see citing works

Expression analysis of dopaminergic neurons in Parkinson’s disease and aging links transcriptional dysregulation of energy metabolism to cell death

Elstner, M., Morris, C. M., Heim, K., Bender, A., Mehta, D., Jaros, E., Klopstock, T., Meitinger, T., Turnbull, D. M., & Prokisch, H. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0828-9 · Cited by 145 · see citing works

Targeting mTOR with rapamycin: One dose does not fit all

Foster, D. A., & Toschi, A. (2009) · Cell Cycle · doi:10.4161/cc.8.7.8044 · Cited by 143 · see citing works

Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist Stimulates Insulin Secretion in Rodents and From Human Islets

Sloop, K. W., Willard, F. S., Brenner, M. B., Ficorilli, J., Valasek, K., Showalter, A. D., Farb, T. B., Cao, J. X. C., Cox, A. L., Michael, M. D., et al. (2010) · Diabetes · doi:10.2337/db10-0689 · Cited by 143 · see citing works

Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats

Han, W.-N., Hölscher, C., Yuan, L., Yang, W., Wang, X., Wu, M., & Qi, J. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.04.009 · Cited by 138 · see citing works

Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer’s disease by exendin-4

Chen, S., Liu, A., An, F.-M., Yao, W., & Gao, X. (2011) · AGE · doi:10.1007/s11357-011-9303-8 · Cited by 136 · see citing works

Hippocampal head atrophy predominance in Parkinson’s disease with hallucinations and with dementia

Ibarretxe‐Bilbao, N., Ramírez‐Ruiz, B., Tolosa, E., Martı́, M. J., Valldeoriola, F., Bargalló, N., & Junqué, C. (2008) · Journal of Neurology · doi:10.1007/s00415-008-0885-8 · Cited by 134 · see citing works

Exendin-4 Ameliorates Motor Neuron Degeneration in Cellular and Animal Models of Amyotrophic Lateral Sclerosis

Li, Y., Chigurupati, S., Holloway, H. W., Mughal, M. R., Tweedie, D., Bruestle, D. A., Mattson, M. P., Wang, Y., Harvey, B. K., Ray, B., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032008 · Cited by 131 · see citing works

Insulin receptor mRNA in the substantia nigra in Parkinson's disease.

Takahashi, M., Yamada, T., Tooyama, I., Moroo, I., Kimura, H., Yamamoto, T., & Okada, H. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12357-0 · Cited by 131 · see citing works

GLP‐1 receptor agonists vs. DPP‐4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?

Brunton, S. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12361 · Cited by 130 · see citing works

Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies

Rees, K., Stowe, R. L., Patel, S., Ives, N. J., Breen, K. C., Clarke, C. E., & Ben‐Shlomo, Y. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008454 · Cited by 130 · see citing works

Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats

Darsalia, V., Mansouri, S., Ortsäter, H., Olverling, A., Nozadze, N., Krizhanovskii, C., Iverfeldt, K., Tracy, L. M., Grankvist, N., Sjöholm, Å., et al. (2011) · Clinical Science · doi:10.1042/cs20110374 · Cited by 129 · see citing works

Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson's disease

Gallegos, S., Pacheco, C. R., Peters, C., Opazo, C., & Aguayo, L. G. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00059 · Cited by 128 · see citing works

Hippocampal abnormalities and memory deficits in Parkinson disease

Carlesimo, G. A., Piras, F., Assogna, F., Pontieri, F. E., Caltagirone, C., & Spalletta, G. (2012) · Neurology · doi:10.1212/wnl.0b013e318259e1c5 · Cited by 126 · see citing works

Saxagliptin: A novel antiparkinsonian approach

Nassar, N. N., Al‐Shorbagy, M. Y., Arab, H. H., & Abdallah, D. M. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.10.007 · Cited by 122 · see citing works

Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies

Rees, K., Stowe, R. L., Patel, S., Ives, N. J., Breen, K. C., Clarke, C. E., & Ben‐Shlomo, Y. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008454.pub2 · Cited by 122 · see citing works

SIRT1 metabolic actions: Integrating recent advances from mouse models

Boutant, M., & Cantó, C. (2013) · Molecular Metabolism · doi:10.1016/j.molmet.2013.10.006 · Cited by 121 · see citing works

Ciliary neurotrophic factor recruitment of glucagon‐like peptide‐1 mediates neurogenesis, allowing immortalization of adult murine hypothalamic neurons

Belsham, D. D., Fick, L. J., Dalvi, P. S., Centeno, M.-L., Chalmers, J. A., Lee, P. K. P., Wang, Y., Drucker, D. J., & Koletar, M. M. (2009) · The FASEB Journal · doi:10.1096/fj.09-133454 · Cited by 120 · see citing works

Insulin-degrading enzyme prevents α-synuclein fibril formation in a nonproteolytical manner

Sharma, S., Chorell, E., Steneberg, P., Vernersson-Lindahl, E., Edlund, H., & Wittung-Stafshede, P. E. (2015) · Scientific Reports · doi:10.1038/srep12531 · Cited by 119 · see citing works

Ischemia‐induced changes in glucagon‐like peptide‐1 receptor and neuroprotective effect of its agonist, exendin‐4, in experimental transient cerebral ischemia

Lee, C. H., Yan, B., Yoo, K., Choi, J. H., Kwon, S., Her, S., Sohn, Y., Hwang, I. K., Cho, J. H., Kim, Y., et al. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22596 · Cited by 118 · see citing works

Suppression of Nuclear Factor-κB Activation and Inflammation in Microglia by Physically Modified Saline

Khasnavis, S., Jana, A., Roy, A., Mazumder, M., Bhushan, B., Wood, T., Ghosh, S., Watson, R. L., & Pahan, K. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.338012 · Cited by 117 · see citing works

SIRT1 Mediates the Effect of GLP-1 Receptor Agonist Exenatide on Ameliorating Hepatic Steatosis

Xu, F., Li, Z., Zheng, X., Liu, H., Liang, H., Xu, H., Chen, Z., Zeng, K., & Weng, J. (2014) · Diabetes · doi:10.2337/db14-0263 · Cited by 114 · see citing works

Metabolic inflammation exacerbates dopaminergic neuronal degeneration in response to acute MPTP challenge in type 2 diabetes mice

Wang, X., Zhai, Y., Xu, L., Qiao, C., Sun, X., Ding, J., Lu, M., & Hu, G. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.11.001 · Cited by 112 · see citing works

Beneficial Effects of Exendin-4 on Experimental Polyneuropathy in Diabetic Mice

Himeno, T., Kamiya, H., Naruse, K., Harada, N., Ozaki, N., Seino, Y., Shibata, T., Kondo, M., Kato, J., Okawa, T., et al. (2011) · Diabetes · doi:10.2337/db10-1462 · Cited by 112 · see citing works

Neuroprotective effects of geniposide in the MPTP mouse model of Parkinson's disease

Chen, Y., Zhang, Y., Li, L., & Hölscher, C. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.09.029 · Cited by 111 · see citing works

The molecular mechanism of rotenone-induced α-synuclein aggregation: Emphasizing the role of the calcium/GSK3β pathway

Yuan, Y., Yan, W.-F., Sun, J., Huang, J., Mu, Z., & Chen, N. (2014) · Toxicology Letters · doi:10.1016/j.toxlet.2014.11.029 · Cited by 111 · see citing works

Effects of Exendin-4 on bone marrow mesenchymal stem cell proliferation, migration and apoptosis in vitro

Zhou, H., Li, D., Chen, S., Xin, T., Yang, J., Zhou, Y. Y., Hu, S., Tian, F., Wang, J., & Chen, Y. (2015) · Scientific Reports · doi:10.1038/srep12898 · Cited by 110 · see citing works

Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1

Parkes, D. G., Mace, K. F., & TRAUTMANN, M. E. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.741580 · Cited by 109 · see citing works

Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction

Chen, Y.-T., Tsai, T., Yang, C.-C., Sun, C., Chang, L., Chen, H.-H., Chang, C.-L., Sung, P., Zhen, Y., Leu, S., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-270 · Cited by 109 · see citing works

Exenatide: a review from pharmacology to clinical practice

Gentilella, R., Bianchi, C., Rossi, A., & Rotella, C. M. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.01018.x · Cited by 108 · see citing works

GLP-1 secretion by microglial cells and decreased CNS expression in obesity

Kappe, C., Tracy, L. M., Patrone, C., Iverfeldt, K., & Sjöholm, Å. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-276 · Cited by 107 · see citing works

The PKB/FOXO switch in aging and cancer

Kloet, D. E. A., & Burgering, B. M. T. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.04.003 · Cited by 104 · see citing works

CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease

Terrelonge, M., Marder, K. S., Weintraub, D. A., & Alcalay, R. N. (2015) · Journal of Molecular Neuroscience · doi:10.1007/s12031-015-0647-x · Cited by 102 · see citing works

Association of PGC-1alphapolymorphisms with age of onset and risk of Parkinson's disease

Clark, J., Reddy, S., Zheng, K., Betensky, R. A., & Simon, D. K. (2011) · BMC Medical Genetics · doi:10.1186/1471-2350-12-69 · Cited by 102 · see citing works

Central Proliferation and Neurogenesis Is Impaired in Type 2 Diabetes and Prediabetes Animal Models

Ramos‐Rodríguez, J. J., Gil, S. M., Ortiz-Barajas, O., Jiménez-Palomares, M., Perdomo, G., Cózar‐Castellano, I., Lechuga-Sancho, A. M., & Garcı́a-Alloza, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089229 · Cited by 102 · see citing works

Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model

Kohl, Z., Winner, B., Ubhi, K., Rockenstein, E., Mante, M., Münch, M., Barlow, C., Carter, T., Masliah, E., & Winkler, J. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2011.07933.x · Cited by 101 · see citing works

A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson′s disease by increasing expression of BNDF

Ji, C., Xue, G., Cao, L., Feng, P., Li, D., Li, L., Li, G., & Hölscher, C. (2015) · Brain Research · doi:10.1016/j.brainres.2015.09.035 · Cited by 101 · see citing works

Impact of mitochondrial calcium on the coupling of metabolism to insulin secretion in the pancreatic β-cell

Wiederkehr, A., & Wollheim, C. B. (2008) · Cell Calcium · doi:10.1016/j.ceca.2007.11.004 · Cited by 100 · see citing works

Val8-glucagon-like peptide-1 protects against Aβ1–40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats

Wang, X. H., Li, L., Hölscher, C., Pan, Y. F., Chen, X. R., & Qi, J. S. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.08.028 · Cited by 99 · see citing works

Enhanced susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in high-fat diet-induced obesity

Choi, J., Jang, E.-H., Park, C., & Kang, J. (2005) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.12.008 · Cited by 98 · see citing works

Alpha-synuclein overexpression negatively regulates insulin receptor substrate 1 by activating mTORC1/S6K1 signaling

Gao, S., Duan, C., Gao, G., Wang, X., & Yang, H. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.03.006 · Cited by 98 · see citing works

Brain Insulin-Like Growth Factor and Neurotrophin Resistance in Parkinson's Disease and Dementia with Lewy Bodies: Potential Role of Manganese Neurotoxicity

Tong, M., Dong, M., & de la Monte, S. M. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-0995 · Cited by 96 · see citing works

Exenatide reduces TNF-α expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats

Solmaz, V., Çınar, B. P., Yiğittürk, G., Çavuşoğlu, T., Taşkıran, D., & Erbaş, O. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.09.024 · Cited by 96 · see citing works

Subcutaneous Administration of Liraglutide Ameliorates Alzheimer-Associated Tau Hyperphosphorylation in Rats with Type 2 Diabetes1

Yang, Y., Zhang, J., Ma, D., Zhang, M., Hu, S., Shao, S., & Gong, C. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130491 · Cited by 92 · see citing works

Exendin-4 Reduces Ischemic Brain Injury in Normal and Aged Type 2 Diabetic Mice and Promotes Microglial M2 Polarization

Darsalia, V., Hua, S., Larsson, M., Mallard, C., Nathanson, D., Nyström, T., Sjöholm, Å., Johansson, M. E., & Patrone, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103114 · Cited by 92 · see citing works

Inhibition of IκB Kinase-β Protects Dopamine Neurons Against Lipopolysaccharide-Induced Neurotoxicity

Zhang, F., Li, Q., Flood, P. M., Shi, J., Hong, J., & Gao, H. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.165829 · Cited by 92 · see citing works

Glucagon‐like peptide‐1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study

Ahern, T., Tobin, A., Corrigan, M., Hogan, A. E., Sweeney, C. M., Kirby, B., & O'Shea, D. B. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2012.04609.x · Cited by 91 · see citing works

Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice

Tweedie, D., Rachmany, L., Rubovitch, V., Lehrmann, E., Zhang, Y., Becker, K. G., Perez, E., Miller, J. P., Hoffer, B. J., Greig, N. H., et al. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.10.001 · Cited by 90 · see citing works

Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Reduces Alzheimer Disease-Associated Tau Hyperphosphorylation in the Hippocampus of Rats with Type 2 Diabetes

Xu, W., Yang, Y., Yuan, G., Zhu, W., Ma, D., & Hu, S. (2015) · Journal of Investigative Medicine · doi:10.1097/jim.0000000000000129 · Cited by 90 · see citing works

Selective autophagy in the maintenance of cellular homeostasis in aging organisms

Hubbard, V. M., Valdor, R., Macián, F., & Cuervo, A. M. (2011) · Biogerontology · doi:10.1007/s10522-011-9331-x · Cited by 89 · see citing works

Adult Hippocampal Neurogenesis in Parkinson’s Disease: Impact on Neuronal Survival and Plasticity

Regensburger, M., Prots, I., & Winner, B. (2014) · Neural Plasticity · doi:10.1155/2014/454696 · Cited by 85 · see citing works

Glucagon-like peptide 1 regulates adipogenesis in 3T3-L1 preadipocytes

YANG, J., REN, J., SONG, J., LIU, F., WU, C., WANG, X., GONG, L., LI, W., XIAO, F., YAN, F., et al. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1350 · Cited by 84 · see citing works

Volumetric analysis of the substantia innominata in patients with Parkinson's disease according to cognitive status

Choi, S. H., Jung, T.-M., Lee, J. E., Lee, S., Sohn, Y. H., & Lee, P. H. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.11.015 · Cited by 83 · see citing works

INSULIN RESISTANCE AND GRAY MATTER VOLUME IN NEURODEGENERATIVE DISEASE

Morris, J. K., Vidoni, E., Perea, R., Rada, R. C., Johnson, D. K., Lyons, K., Pahwa, R., Burns, J. M., & Honea, R. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.04.006 · Cited by 81 · see citing works

Glucagon-Like Peptide 1, Insulin, Sensory Neurons, and Diabetic Neuropathy

Kan, M., Guo, G., Singh, B., Singh, V., & Zochodne, D. W. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182580673 · Cited by 80 · see citing works

Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal synaptic plasticity and metabolic control in high-fat fed mice

Lennox, R., Porter, D. W., Flatt, P. R., Hölscher, C., Irwin, N., & Gault, V. A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.06.026 · Cited by 78 · see citing works

Association between AKT1 gene and Parkinson's disease: A protective haplotype

Xiromerisiou, G., Hadjigeorgiou, G. M., Papadimitriou, A., Katsarogiannis, E., Gourbali, V., & Singleton, A. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.03.026 · Cited by 77 · see citing works

Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice

Porter, W. D., Flatt, P. R., Hölscher, C., & Gault, V. A. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.91 · Cited by 76 · see citing works

Selective induction of neocortical GABAergic neurons by the PDK1-Akt pathway through activation of Mash1

Oishi, K., Watatani, K., Itoh, Y., Okano, H., Guillemot, F., Nakajima, K., & Gotoh, Y. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808400106 · Cited by 75 · see citing works

Early intervention with glucagon‐like peptide 1 analog liraglutide prevents tau hyperphosphorylation in diabetic db/db mice

Ma, D., Chen, F., Xu, W., Yue, W., Yuan, G., & Yang, Y. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13248 · Cited by 73 · see citing works

Differential Effects of Proteases Involved in Intracellular Degradation of Amyloid β-Protein between Detergent-Soluble and -Insoluble Pools in CHO-695 Cells

Sudoh, S., Frosch, M. P., & Wolf, B. A. (2002) · Biochemistry · doi:10.1021/bi011193l · Cited by 73 · see citing works

Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury

Greig, N. H., Tweedie, D., Rachmany, L., Li, Y., Rubovitch, V., Schreiber, S., Chiang, Y. H., Hoffer, B. J., Miller, J. P., Lahiri, D. K., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.12.011 · Cited by 71 · see citing works

Repeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats

Briyal, S., Gulati, K., & Gulati, A. (2011) · Brain Research · doi:10.1016/j.brainres.2011.10.026 · Cited by 71 · see citing works

Mutated recombinant human glucagon-like peptide-1 protects SH-SY5Y cells from apoptosis induced by amyloid-beta peptide (1-42).

Qin, Z., Sun, Z.-W., Huang, J., Hu, Y.-H., Wu, Z.-R., & Mei, B. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.08.047 · Cited by 70 · see citing works

Glucagon-Like Peptide-1 Increases Mitochondrial Biogenesis and Function in INS-1 Rat Insulinoma Cells

Kang, M. Y., Oh, T. J., & Cho, Y. M. (2015) · Endocrinology and Metabolism · doi:10.3803/enm.2015.30.2.216 · Cited by 70 · see citing works

Akt as a Victim, Villain and Potential Hero in Parkinson’s Disease Pathophysiology and Treatment

Greene, L. A., Levy, O., & Malagelada, C. (2011) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-011-9671-8 · Cited by 68 · see citing works

Exendin-4 Ameliorates Traumatic Brain Injury-Induced Cognitive Impairment in Rats

Eakin, K. C., Li, Y., Chiang, Y. H., Hoffer, B. J., Rosenheim, H. M., Greig, N. H., & Miller, J. P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082016 · Cited by 67 · see citing works

A role for sphingolipids in the pathophysiology of obesity-induced inflammation

Bikman, B. T. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-0917-5 · Cited by 67 · see citing works

Destruction of Dopaminergic Neurons in the Midbrain by 6-Hydroxydopamine Decreases Hippocampal Cell Proliferation in Rats: Reversal by Fluoxetine

Suzuki, K., Okada, K., Wakuda, T., Shinmura, C., Kameno, Y., Iwata, K., Takahashi, T., Suda, S., Matsuzaki, H., Iwata, Y., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009260 · Cited by 66 · see citing works

GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats

Sharma, A. N., Ligade, S. S., Sharma, J. N., Shukla, P., Elased, K. M., & Lucot, J. B. (2014) · Metabolic Brain Disease · doi:10.1007/s11011-014-9591-7 · Cited by 66 · see citing works

Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation

Chen, S., An, F.-M., Yin, L., Liu, A.-R., Yin, D.-K., Yao, W.-B., & Gao, X.-D. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.10.038 · Cited by 64 · see citing works

Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium

DeNicola, M., Du, J., Wang, Z., Yano, N., Zhang, L., Wang, Y., Qin, G., Zhuang, S., & Zhao, T. C. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00109.2014 · Cited by 62 · see citing works

Depression and Cognitive Impairment in Parkinson's Disease: A Role for Inflammation and Immunomodulation?

Rocha, N. P., Reis, H. J., Berghe, P. V., & Cirillo, C. (2014) · NeuroImmunoModulation · doi:10.1159/000356531 · Cited by 61 · see citing works

Neuroprotective effects of geniposide on Alzheimer’s disease pathology

Liu, W., Li, G., Hölscher, C., & Li, L. (2015) · Reviews in the Neurosciences · doi:10.1515/revneuro-2015-0005 · Cited by 60 · see citing works

Exenatide and weight loss

Bradley, D. P., Kulstad, R., & Schoeller, D. A. (2010) · Nutrition · doi:10.1016/j.nut.2009.07.008 · Cited by 59 · see citing works

Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease

Yun, S. P., Kam, T.-I., Panicker, N., Kim, S., Oh, Y., Park, J.-S., Kwon, S.-H., Park, Y. J., Karuppagounder, S. S., Park, H., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0051-5 · Cited by 1,123 · see citing works

Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing

Cunnane, S. C., Trushina, E., Morland, C., Prigione, A., Casadesus, G., Andrews, Z. B., Beal, M. F., Bergersen, L. H., Brinton, R. D., de la Monte, S., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0072-x · Cited by 1,003 · see citing works

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889 · see citing works

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721135 · Cited by 463 · see citing works

Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations

Lang, A. E., & Espay, A. J. (2018) · Movement Disorders · doi:10.1002/mds.27360 · Cited by 374 · see citing works

Insulin resistance and Parkinson’s disease: A new target for disease modification?

Athauda, D. S., & Foltynie, T. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.10.001 · Cited by 333 · see citing works

Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent

Mehdi, S. F., Pusapati, S., Anwar, M. S., Lohana, D., Kumar, P., Nandula, S. A., Nawaz, F. K., Tracey, K., Yang, H., LeRoith, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148209 · Cited by 317 · see citing works

Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function

Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302 · see citing works

Emerging therapies in Parkinson disease — repurposed drugs and new approaches

Elkouzi, A., Vedam‐Mai, V., Eisinger, R. S., & Okun, M. S. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0155-7 · Cited by 304 · see citing works

Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs

Charvin, D., Medori, R., Hauser, R. A., & Rascol, O. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.136 · Cited by 285 · see citing works

Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson’s disease

Hou, Y.-F., Shan, C., Zhuang, S.-Y., Zhuang, Q.-Q., Ghosh, A., Zhu, K.-C., Kong, X.-K., Wang, S.-M., Gong, Y.-L., Yang, Y.-Y., et al. (2021) · Microbiome · doi:10.1186/s40168-020-00988-6 · Cited by 231 · see citing works

The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non‐human primate model of Alzheimer's disease

Batista, A. F., Forny‐Germano, L., Clarke, J. R., Silva, N. M. L. E., Brito‐Moreira, J., Boehnke, S. E., Winterborn, A., Coe, B. C., Lablans, A., Vital, J. F. S., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5056 · Cited by 246 · see citing works

Impairment of insulin signaling pathway PI3K/Akt/mTOR and insulin resistance induced AGEs on diabetes mellitus and neurodegenerative diseases: a perspective review

Ramasubbu, K., & Rajeswari, V. D. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04587-x · Cited by 249 · see citing works

Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases

Grieco, M., Giorgi, A., Gentile, M. C., d’Erme, M., Morano, S., Maras, B., & Filardi, T. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01112 · Cited by 218 · see citing works

The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis

Chen, X., Zhao, P., Wang, W., Guo, L., & Pan, Q. (2024) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2023.08.010 · Cited by 185 · see citing works

α-Synuclein and astrocytes: tracing the pathways from homeostasis to neurodegeneration in Lewy body disease

Sorrentino, Z. A., Giasson, B. I., & Chakrabarty, P. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01977-2 · Cited by 181 · see citing works

Recent developments in the treatment of Parkinson's Disease

Stoker, T. B., & Barker, R. A. (2020) · F1000Research · doi:10.12688/f1000research.25634.1 · Cited by 168 · see citing works

Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson’s Disease

Zhang, L., Zhang, L., Li, L., & Hölscher, C. (2019) · Journal of Parkinson's Disease · doi:10.3233/jpd-181503 · Cited by 173 · see citing works

Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases

Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179583 · Cited by 148 · see citing works

GLP-1 Receptor Agonist NLY01 Reduces Retinal Inflammation and Neuron Death Secondary to Ocular Hypertension

Sterling, J. K., Adetunji, M. O., Guttha, S., Bargoud, A. R., Uyhazi, K. E., Ross, A. G., Dunaief, J. L., & Cui, Q. N. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108271 · Cited by 148 · see citing works

Diet in Parkinson’s Disease: Critical Role for the Microbiome

Jackson, A., Forsyth, C. B., Shaikh, M., Voigt, R. M., Engen, P. A., Ramirez, V., & Keshavarzian, A. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01245 · Cited by 145 · see citing works

Diabetes drugs in the fight against Alzheimer's disease

Boccardi, V., Murasecco, I., & Mecocci, P. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100936 · Cited by 142 · see citing works

Management of hypoglycemia in older adults with type 2 diabetes

Freeman, J. S. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1578590 · Cited by 144 · see citing works

Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2020

McFarthing, K., Buff, S., Rafaloff, G., Dominey, T., Wyse, R. K. H., & Stott, S. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-202128 · Cited by 138 · see citing works

A New Treatment Strategy for Parkinson's Disease through the Gut–Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway

Kim, D. S., Choi, H.-I., Wang, Y., Luo, Y., Hoffer, B. J., & Greig, N. H. (2017) · Cell Transplantation · doi:10.1177/0963689717721234 · Cited by 136 · see citing works

Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease

Nowell, J., Blunt, E., & Edison, P. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01792-4 · Cited by 136 · see citing works

Vildagliptin Attenuates Huntington's Disease through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model

Sayed, N. H., Fathy, N., Kortam, M. A., Rabie, M. A., Mohamed, A. F., & Kamel, A. S. E. D. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00805-5 · Cited by 134 · see citing works

Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions

Imbernon, M., Saponaro, C., Helms, H. C. C., Duquenne, M., Fernandois, D., Deligia, E., Denis, R. G. P., Chao, D. H. M., Rasika, S., Staels, B., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.06.002 · Cited by 124 · see citing works

Recent Advances in Drug Therapy for Parkinson's Disease

Murakami, H., Shiraishi, T., Umehara, T., Omoto, S., & Iguchi, Y. (2022) · Internal Medicine · doi:10.2169/internalmedicine.8940-21 · Cited by 114 · see citing works

Alleviation of depression by glucagon-like peptide 1 through the regulation of Neuroinflammation, neurotransmitters, neurogenesis, and synaptic function

Kim, Y.-K., Kim, O. Y., & Song, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01270 · Cited by 109 · see citing works

Emerging Therapeutic Strategies for Parkinson’s Disease and Future Prospects: A 2021 Update

Gouda, N., Elkamhawy, A., & Cho, J. (2022) · Biomedicines · doi:10.3390/biomedicines10020371 · Cited by 94 · see citing works

GLP-1a: Going beyond Traditional Use

Laurindo, L. F., Barbalho, S. M., Guiguer, E. L., da Silva Soares de Souza, M., de Souza, G. A., Fidalgo, T. M., Araújo, A. C., de Souza Gonzaga, H. F., de Bortoli Teixeira, D., de Oliveira Silva Ullmann, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020739 · Cited by 102 · see citing works

GLP-1 mimetics and cognition.

Yaribeygi, H., Rashidy-Pour, A., Atkin, S. L., Jamialahmadi, T., & Sahebkar, A. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118645 · Cited by 96 · see citing works

Psychobiotics: the Influence of Gut Microbiota on the Gut-Brain Axis in Neurological Disorders

Oroojzadeh, P., Bostanabad, S. Y., & Lotfi, H. (2022) · Journal of Molecular Neuroscience · doi:10.1007/s12031-022-02053-3 · Cited by 105 · see citing works

Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease

Athauda, D. S., & Foltynie, T. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.09.023 · Cited by 97 · see citing works

GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes

Monney, M., Jornayvaz, F. R., & Gariani, K. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101470 · Cited by 94 · see citing works

Glucagon like peptide-1 (GLP-1) likes Alzheimer’s disease

Simsir, I. Y., Soyaltın, U. E., & Çetinkalp, Ş. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.03.002 · Cited by 92 · see citing works

High Prevalence of Undiagnosed Insulin Resistance in Non-Diabetic Subjects with Parkinson’s Disease

Hogg, E. J., Athreya, K., Basile, C., Tan, E. E., Kamiński, J. P., & Tagliati, M. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-181305 · Cited by 91 · see citing works

Autocrine Interleukin-10 Mediates Glucagon-Like Peptide-1 Receptor-Induced Spinal Microglial β-Endorphin Expression

Wu, H., Tang, X.-Q., Mao, X.-F., & Wang, Y. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.1799-17.2017 · Cited by 87 · see citing works

Diabetes, a Contemporary Risk for Parkinson’s Disease: Epidemiological and Cellular Evidences

Sergi, D., Renaud, J., Simola, N., & Martinoli, M. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00302 · Cited by 85 · see citing works

Toll-Like Receptor 4: A Promising Therapeutic Target for Alzheimer’s Disease

Wu, L., Xian, X., Xu, G., Tan, Z., Dong, F., Zhang, M., & Zhang, F. (2022) · Mediators of Inflammation · doi:10.1155/2022/7924199 · Cited by 85 · see citing works

Neuroendocrine abnormalities in Parkinson's disease

Pablo‐Fernández, E. D., Breen, D. P., Bouloux, P. M., Barker, R. A., Foltynie, T., & Warner, T. T. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-314601 · Cited by 83 · see citing works

Diabetes Mellitus and Parkinson's Disease: Shared Pathophysiological Links and Possible Therapeutic Implications

Hassan, A. T., Kandel, R. S., Mishra, R., Gautam, J., Alaref, A. A., & Jahan, N. (2020) · Cureus · doi:10.7759/cureus.9853 · Cited by 74 · see citing works

Activation of microglial GLP-1R in the trigeminal nucleus caudalis suppresses central sensitization of chronic migraine after recurrent nitroglycerin stimulation

Jing, F., Zou, Q., Wang, Y., Cai, Z., & Tang, Y. C. (2021) · The Journal of Headache and Pain · doi:10.1186/s10194-021-01302-x · Cited by 76 · see citing works

The role of glia in the physiology and pharmacology of glucagon‐like peptide‐1: implications for obesity, diabetes, neurodegeneration and glaucoma

Cui, Q. N., Stein, L. M., Fortin, S. M., & Hayes, M. R. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15683 · Cited by 71 · see citing works

Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer’s disease and Parkinson’s disease

Fang, X., Zhou, X., Miao, Y., Han, Y., Wei, J., & Chen, T. (2020) · AMB Express · doi:10.1186/s13568-020-01014-6 · Cited by 70 · see citing works

Neuromodulatory effects of anti-diabetes medications: A mechanistic review

Yaribeygi, H., Ashrafizadeh, M., Henney, N. C., Sathyapalan, T., Jamialahmadi, T., & Sahebkar, A. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104611 · Cited by 70 · see citing works

GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight

Monti, G., Moreira, D. G., Richner, M., Mutsaers, H. A. M., Ferreira, N., & Jan, A. (2022) · Cells · doi:10.3390/cells11132023 · Cited by 69 · see citing works

Exenatide exerts cognitive effects by modulating the BDNF-TrkB neurotrophic axis in adult mice

Bomba, M., Granzotto, A., Castelli, V., Massetti, N., Silvestri, E., Canzoniero, L. M. T., Cimini, A., & Sensi, S. L. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.12.009 · Cited by 69 · see citing works

Sitagliptin enhances the neuroprotective effect of pregabalin against pentylenetetrazole-induced acute epileptogenesis in mice: Implication of oxidative, inflammatory, apoptotic and autophagy pathways

Nader, M. A., Ateyya, H., El‐Shafey, M., & El-Sherbeeny, N. A. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.10.006 · Cited by 68 · see citing works

Liraglutide ameliorated peripheral neuropathy in diabetic rats: Involvement of oxidative stress, inflammation and extracellular matrix remodeling

Moustafa, P. E., Abdelkader, N. F., Awdan, S. A. E., El‐Shabrawy, O. A., & Zaki, H. F. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14336 · Cited by 68 · see citing works

Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease

Chen, S., Yu, S., Li, Y., Lecca, D., Glotfelty, E. J., Kim, H. K., Choi, H., Hoffer, B. J., Greig, N. H., Kim, D. S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28449-z · Cited by 68 · see citing works

Recent advances in understanding the role of glucagon-like peptide 1

Reed, J., Bain, S., & Kanamarlapudi, V. (2020) · F1000Research · doi:10.12688/f1000research.20602.1 · Cited by 66 · see citing works

Diabetes Mellitus and Parkinson’s Disease: A Systematic Review and Meta-Analyses

Komici, K., Femminella, G. D., Bencivenga, L., Rengo, G., & Pagano, G. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212725 · Cited by 65 · see citing works

Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases

Chen, S., Chuang, Y., Lin, T., & Yang, J. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175439 · Cited by 66 · see citing works

Associations Between Diabetes Mellitus and Neurodegenerative Diseases

Szablewski, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020542 · Cited by 74 · see citing works

Pathophysiology linking depression and type 2 diabetes: Psychotherapy, physical exercise, and fecal microbiome transplantation as damage control

Subba, R., Sandhir, R., Singh, S. P., Mallick, B. N., & Mondal, A. C. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15136 · Cited by 64 · see citing works

Exenatide Reverts the High-Fat-Diet-Induced Impairment of BDNF Signaling and Inflammatory Response in an Animal Model of Alzheimer's Disease

Bomba, M., Granzotto, A., Castelli, V., ONOFRJ, M. C., Lattanzio, R., Cimini, A., & Sensi, S. L. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-190237 · Cited by 64 · see citing works

The Molecular Mechanisms of the Relationship between Insulin Resistance and Parkinson’s Disease Pathogenesis

Ruiz-Pozo, V. A., Tamayo-Trujillo, R., Cadena-Ullauri, S., Frias-Toral, E., Guevara-Ramírez, P., Paz-Cruz, E., Chapela, S., Montalván, M., Morales-López, T., Simancas-Racines, D., et al. (2023) · Nutrients · doi:10.3390/nu15163585 · Cited by 63 · see citing works

Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors

Suzuki, R., Brown, G. A., Christopher, J. A., Scully, C. C. G., & Congreve, M. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00835 · Cited by 63 · see citing works

Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson’s disease

Glotfelty, E. J., Olson, L., Karlsson, T. E., Li, Y., & Greig, N. H. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1764534 · Cited by 63 · see citing works

Neurotrophic Role of the Next-Generation Probiotic Strain L. lactis MG1363-pMG36e-GLP-1 on Parkinson’s Disease via Inhibiting Ferroptosis

Yue, M., Wei, J., Chen, W., Hong, D., Chen, T., & Fang, X. (2022) · Nutrients · doi:10.3390/nu14224886 · Cited by 62 · see citing works

Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: a systematic review

Halloum, W., Dughem, Y. A., Beier, D., & Pellesi, L. (2024) · The Journal of Headache and Pain · doi:10.1186/s10194-024-01821-3 · Cited by 63 · see citing works

D-Ala2-GIP-glu-PAL is neuroprotective in a chronic Parkinson's disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation

Li, Y., Liu, W., Li, L., & Hölscher, C. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.11.050 · Cited by 62 · see citing works

Liraglutide restores chronic ER stress, autophagy impairments and apoptotic signalling in SH-SY5Y cells

Panagaki, T., Michael, M., & Hölscher, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-16488-x · Cited by 62 · see citing works

Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis

Geloneze, B., Júnior, J. C. D. L., & Velloso, L. A. (2017) · Drugs · doi:10.1007/s40265-017-0706-4 · Cited by 61 · see citing works

Gut microbiome: An intermediary to neurotoxicity

Dempsey, J. L., Little, M., & Cui, J. Y. (2019) · NeuroToxicology · doi:10.1016/j.neuro.2019.08.005 · Cited by 62 · see citing works

Neuroprotective effects of vildagliptin on drug induced Alzheimer's disease in rats with metabolic syndrome: Role of hippocampal klotho and AKT signaling pathways

Rasha, R. Y., El-Yamany, M. F., Saad, M. A., & El-Sahar, A. E. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173612 · Cited by 59 · see citing works

Two Birds One Stone: The Neuroprotective Effect of Antidiabetic Agents on Parkinson Disease—Focus on Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors

Lin, K.-J., Wang, T., Chen, S., Lin, K.-L., Liou, C., Lan, M., Chuang, Y., Chuang, J., Wang, P., Lee, J., et al. (2021) · Antioxidants · doi:10.3390/antiox10121935 · Cited by 60 · see citing works

Drug Repurposing in Parkinson’s Disease

Athauda, D. S., & Foltynie, T. (2018) · CNS Drugs · doi:10.1007/s40263-018-0548-y · Cited by 59 · see citing works

A Stage-Based Approach to Therapy in Parkinson’s Disease

Carrarini, C., Russo, M., Dono, F., Pietro, M. D., Rispoli, M. G., Stefano, V. D., Ferri, L., Barbone, F., Vitale, M., Thomas, A., et al. (2019) · Biomolecules · doi:10.3390/biom9080388 · Cited by 58 · see citing works

Neuroprotective Mechanisms of Glucagon-Like Peptide-1-Based Therapies in Ischemic Stroke: An Update Based on Preclinical Research

Yang, X., Qiang, Q., Li, N., Feng, P., Wei, W., & Hölscher, C. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.844697 · Cited by 58 · see citing works

Neuroprotective effects of an engineered Escherichia coli Nissle 1917 on Parkinson's disease in mice by delivering GLP ‐1 and modulating gut microbiota

Wu, H., Wei, J., Zhao, X., Liu, Y., Chen, Z., Wei, K., Lu, J., Chen, W., Jiang, M., Li, S., et al. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10351 · Cited by 57 · see citing works

Exendin-4 Treatment Improves LPS-Induced Depressive-Like Behavior Without Affecting Pro-Inflammatory Cytokines

Ventorp, F., Bay-Richter, C., Nagendra, A. S., Janelidze, S., Matsson, V. S., Lipton, J., Nordström, U., Westrin, Å., Brundin, P., & Brundin, L. (2017) · Journal of Parkinson’s Disease · doi:10.3233/jpd-171068 · Cited by 56 · see citing works

Chlorogenic Acid: a Polyphenol from Coffee Rendered Neuroprotection Against Rotenone-Induced Parkinson’s Disease by GLP-1 Secretion

Sharma, N., Soni, R., Sharma, M., Chatterjee, S., Parihar, N., Mukarram, M., kale, R., Sayyed, A. A., Behera, S. K., & Khairnar, A. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03005-z · Cited by 54 · see citing works

Neuroprotection of Exendin-4 by Enhanced Autophagy in a Parkinsonian Rat Model of α-Synucleinopathy

Bu, L.-L., Liu, Y., Shen, Y., Fan, Y., Yu, W., Jiang, D., Tang, Y., Yang, Y., Wu, P., Zuo, C., et al. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01018-5 · Cited by 54 · see citing works

GLP-1 receptor agonist liraglutide has a neuroprotective effect on an aged rat model of Wolfram syndrome

Seppa, K., Toots, M., Reimets, R., Jagomäe, T., Koppel, T., Pallase, M., Hasselholt, S., Krogsbaek, M., Nyengaard, J. R., Vasar, E., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-52295-2 · Cited by 53 · see citing works

Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned

Hung, A. Y., & Schwarzschild, M. A. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00964-w · Cited by 52 · see citing works

Biological Membrane-Penetrating Peptides: Computational Prediction and Applications

de Oliveira, E. C. L., da Costa, K. S., Taube, P. S., Lima, A. H., & Sales, C. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.838259 · Cited by 53 · see citing works

Neuroprotective exendin-4 enhances hypothermia therapy in a model of hypoxic-ischaemic encephalopathy

Rocha‐Ferreira, E., Poupon-Bejuit, L., Zelco, A., Leverin, A., Nair, S., Jonsdotter, A., Carlsson, Y., Thornton, C., Hagberg, H., & Rahim, A. A. (2018) · Brain · doi:10.1093/brain/awy220 · Cited by 52 · see citing works

Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents

Mousa, S. A., & Ayoub, B. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.249217 · Cited by 52 · see citing works

Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats

Badawi, G. A., Fattah, M. A. A. E., Zaki, H. F., & Sayed, M. I. E. (2019) · Neurotoxicity Research · doi:10.1007/s12640-019-9998-3 · Cited by 53 · see citing works

The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs—Therapeutic potential exploration in lung injury

Pang, J., Feng, J. N., Ling, W., & Jin, T. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.06.003 · Cited by 52 · see citing works

Brain Endothelial Cells Regulate Glucagon-Like Peptide 1 Entry Into the Brain via a Receptor-Mediated Process

Fu, Z., Gong, L., Liu, J., Wu, J., Barrett, E. J., Aylor, K. W., & Liu, Z. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00555 · Cited by 51 · see citing works

Dementia in Diabetes: The Role of Hypoglycemia

Husain, K. H., Sarhan, S. F., AlKhalifa, H. K. A. A., Buhasan, A., Moin, A. S. M., & Butler, A. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129846 · Cited by 52 · see citing works

Neuroprotective Effects of Eexenatide in a Rotenone-Induced Rat Model of Parkinson’s Disease

Aksoy, D., Solmaz, V., Çavuşoğlu, T., Meral, A., Ateş, U., & Erbaş, O. (2017) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2017.05.002 · Cited by 50 · see citing works

Nrf2/Wnt resilience orchestrates rejuvenation of glia-neuron dialogue in Parkinson's disease

Marchetti, B. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101664 · Cited by 49 · see citing works

Sodium butyrate ameliorates gut dysfunction and motor deficits in a mouse model of Parkinson’s disease by regulating gut microbiota

Zhang, Y., Xu, S., Qian, Y., Mo, C., Ai, P., Yang, X., & Xiao, Q. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1099018 · Cited by 49 · see citing works

Animal Venom Peptides as a Treasure Trove for New Therapeutics Against Neurodegenerative Disorders

Yang, X., Wang, Y., Wu, C., & Ling, E. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181031122438 · Cited by 48 · see citing works

Glucagon-Like Peptide-1 Receptor Agonist Ameliorates 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Neurotoxicity Through Enhancing Mitophagy Flux and Reducing α-Synuclein and Oxidative Stress

Lin, T., Lin, K.-J., Lin, H., Lin, K.-L., Lan, M., Wang, P., Wang, T., Wang, F., Tsai, P.-C., Liou, C., et al. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.697440 · Cited by 50 · see citing works

Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury

Glotfelty, E. J., Delgado, T., Tovar‐y‐Romo, L. B., Luo, Y., Hoffer, B. J., Olson, L., Karlsson, T. E., Mattson, M. P., Harvey, B. K., Tweedie, D., et al. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00003 · Cited by 48 · see citing works

Association between glucagon-Like Peptide-1 receptor agonists and the risk of glaucoma in individuals with type 2 diabetes

Niazi, S., Gnesin, F., Thein, A.-S., Andreasen, J. R., Horwitz, A., Mouhammad, Z. A., Jawad, B. N., Niazi, Z., Pourhadi, N., Zareini, B., et al. (2024) · Ophthalmology · doi:10.1016/j.ophtha.2024.03.004 · Cited by 47 · see citing works

Cell-Penetrating Peptides: Promising Therapeutics and Drug-Delivery Systems for Neurodegenerative Diseases

Pirhaghi, M., Mamashli, F., Moosavi-Movahedi, F., Arghavani, P., Amiri, A., Davaeil, B., Mohammad-Zaheri, M., Mousavi-Jarrahi, Z., Sharma, D., Langel, Ü., et al. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c01167 · Cited by 47 · see citing works

The metabolite GLP‐1 (9‐36) is neuroprotective and anti‐inflammatory in cellular models of neurodegeneration

Li, Y., Glotfelty, E. J., Karlsson, T. E., Fortuno, L. V., Harvey, B. K., & Greig, N. H. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15521 · Cited by 47 · see citing works

Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study

Tsai, W.-H., Sung, F., Chiu, L., Shih, Y., Tsai, M.-C., & Wu, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.765446 · Cited by 47 · see citing works

Glucagon-like Peptide-1 (GLP-1) and neurotransmitters signaling in epilepsy: An insight review

Koshal, P., Jamwal, S., & Kumar, P. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.015 · Cited by 45 · see citing works

The Role of Mitochondria in Immune-Cell-Mediated Tissue Regeneration and Ageing

Su, Y., Wang, P., & Weng, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052668 · Cited by 45 · see citing works

Repurposing anti-diabetic drugs for the treatment of Parkinson's disease: Rationale and clinical experience

Foltynie, T., & Athauda, D. S. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.10.008 · Cited by 44 · see citing works

Role of liraglutide in brain repair promotion through Sirt1‐mediated mitochondrial improvement in stroke

He, W., Wang, H., Zhao, C., Tian, X., Li, L., & Wang, H. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29204 · Cited by 44 · see citing works

Vildagliptin restores cognitive function and mitigates hippocampal neuronal apoptosis in cisplatin-induced chemo-brain: Imperative roles of AMPK/Akt/CREB/ BDNF signaling cascades

Mahmoud, A. M. A., Mantawy, E. M., Wahdan, S. A., Ammar, R. M., & El‐Demerdash, E. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114238 · Cited by 42 · see citing works

Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease

Athauda, D. S., & Foltynie, T. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.09.023 · Cited by 97 · see citing works

Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson’s disease

Yang, X., Feng, P., Ji, R., Ren, Y., Wei, W., & Hölscher, C. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2079492 · Cited by 51 · see citing works

GLP-1 receptor agonists for Parkinson's disease

Mulvaney, C. A., Duarte, G. S., Handley, J. D., Evans, D. J., Menon, S., Wyse, R. K. H., & Emsley, H. C. A. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012990.pub2 · Cited by 69 · see citing works

Glucagon-like Peptide-1 receptor agonists for the prevention and treatment of Parkinson’s disease

Lee, S. M. L., Yin, L., Xiao, N., Rhee, T. G., Lo, H. K. Y., Wong, S., Fox, S. H., Teopiz, K. M., Lam, B. Y., Zheng, Y. J., et al. (2025) · CNS Spectrums · doi:10.1017/s109285292510031x · Cited by 6 · see citing works

Therapeutic Impact of GLP‐1 Receptor Agonists on Parkinson's Disease: A Scoping Review

Henriques, J. P., Rahal, J. P. S., Ribeiro, R. D. C. G., Machado, E. B. R., & Negrato, C. A. (2026) · Neurology and Clinical Neuroscience · doi:10.1002/ncn3.70165